Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetic profile of IV (intravenous) and PO (oral) formulations of
linezolid among children with cystic fibrosis and establish a dose regimen that will be safe
and effective.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics